Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PT UBC Medical Indonesia Tbk's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 86.28.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PT UBC Medical Indonesia Tbk's liquidation value for the
three
months ended in Jun. 2026 was Rp20,804 Mil.
PT UBC Medical Indonesia Tbk (ISX:LABS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PT UBC Medical Indonesia Tbk's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of liquidation value, PT UBC Medical Indonesia Tbk's accounts receivable are only considered to be worth 75% of book value:
PT UBC Medical Indonesia Tbk's liquidation value for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT UBC Medical Indonesia Tbk Change In Receivables Related Terms
PT UBC Medical Indonesia Tbk Change In Receivables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT UBC Medical Indonesia Tbk Change In Receivables Chart
PT UBC Medical Indonesia Tbk Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT UBC Medical Indonesia Tbk (ISX:LABS) has a Change In Receivables of Rp Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT UBC Medical Indonesia Tbk and its competitors.
Is PT UBC Medical Indonesia Tbk's Change In Receivables too high?
PT UBC Medical Indonesia Tbk's current Change In Receivables is Rp Mil. Overall, PT UBC Medical Indonesia Tbk has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does PT UBC Medical Indonesia Tbk's Change In Receivables compare to ABT and SYK?
PT UBC Medical Indonesia Tbk's Change In Receivables of Rp Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT UBC Medical Indonesia Tbk and its competitors. PT UBC Medical Indonesia Tbk's current Change In Receivables is Rp Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT UBC Medical Indonesia Tbk stock overvalued right now?
PT UBC Medical Indonesia Tbk (ISX:LABS) has a current Change In Receivables of Rp Mil. The current Change In Receivables is Rp Mil. PT UBC Medical Indonesia Tbk's overall GF Score™ is 2/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PT UBC Medical Indonesia Tbk (ISX:LABS), the current Change In Receivables is Rp Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT UBC Medical Indonesia Tbk is a distribution company. It engages in wholesale of Laboratory Equipment, Pharmaceutical Equipment, and Medical Equipment for Humans and animals, which includes the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment. It divides its main marketed medical equipment products into two categories Instruments, in the form of equipment, machines, and analyzers, are used in laboratories. The function of instruments is to process specimens or biological samples to measure and examine the levels of certain substances/contents; and Consumables include single-use medical devices used for treatment or health examinations and Reagents include chemical reagents used in laboratory tests to detect, measure, examine, & produce other substances.
2GF Score
Get the complete analysis for ISX:LABS
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:LABS has been successfully added to your 
